The company welcomes new development partnerships and collaborations with both industry and academia for its proprietary oral T-cell activation therapy platform and product candidates. VAXIMM works with leading academic institutions in its development activities.
For more information, please contact us.
Then you will be automatically forwarded to our email form.
In May 2017, VAXIMM announced a scientific collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials with this combination – one in glioblastoma and one in metastatic colorectal cancer.